New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 25, 2012
06:01 EDTACTG, VARAcacia Research unit enters into settlement agreement with Varian Medical
Acacia Research Corporation (ACTG) announced that its Brain Life LLC subsidiary has entered into a settlement agreement with Varian Medical Systems (VAR). The agreement resolves litigation that was pending in the United States District Court for the Southern District of California.
News For ACTG;VAR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
16:04 EDTVARVarian Medical awarded $23M order to equip hospitals in Spain
Subscribe for More Information
July 29, 2015
16:41 EDTVARVarian Medical down 3.8% after reporting Q3 earnings, acquires Claymount
16:40 EDTVARVarian Medical acquires Claymount for EUR 50M
Subscribe for More Information
16:39 EDTVARVarian Medical raises FY15 EPS view to $4.20-$4.25 from $4.02-$4.14
Subscribe for More Information
16:37 EDTVARVarian Medical reports Q3 EPS $1.13, consensus $1.11
Subscribe for More Information
July 27, 2015
08:07 EDTVARVarian Medical selected by NHS to equip two therapy centers
Subscribe for More Information
July 23, 2015
16:04 EDTACTGAcacia Research reports Q2 adjusted EPS 25c, three estimates 3c
Subscribe for More Information
July 21, 2015
08:35 EDTVARVarian Medical signs agreement to operate first proton facility in New York
Varian Medical Systems (VAR) announced that it has entered into an agreement with New York Proton Management, a consortium of leading New York healthcare institutions including Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Montefiore Health System, and ProHEALTH Medical Management formed to operate The New York Proton Center, the first proton facility in New York State. Varian will provide the center, which will have four treatment rooms and a research room, with its ProBeam system, as well as 10 years of service for approximately $115M. The center, which will be located in Manhattan, is expected to open for treatment in the first half of 2018. Varian expects to book the equipment portion of the order in Q4 with the remainder of the order to be booked in accordance with the company's policies over the term of the agreement. Under an agreement with MM Proton I, LLC, the project developer, Varian's international subsidiary in Switzerland will provide $91.5M in project financing, including a six-and-half-year $73M senior first lien loan at 9% interest and a six-and-half-year $18.5M subordinate loan at up to 13.5% interest. Other lenders for the $242.7M in total project loans include JPMorgan Chase Bank (JPM) and an affiliate of The Goldman Sachs Group (GS). The project facility is managed by Murphy & McManus, a Boston-based developer of healthcare and life science facilities and Norton Travis of NLT Advisors served as project coordinator on behalf of the consortium.
06:02 EDTACTGAcacia Research subsidiary sources rights in technology patent portfolio
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use